NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., has closed the first tranche of its non-brokered private placement, raising C$2.7 million. The company sold 22.5 million units at C$0.12 per unit, with each unit consisting of one common share and one common share purchase warrant. The warrants allow holders to purchase an additional common share at US$0.115 (approximately C$0.16) until August 12, 2029, and include an acceleration provision tied to a potential Nasdaq listing.
The proceeds from this tranche are earmarked for general working capital, including the evaluation of prospective transactions, settlement of liabilities, and repayment of outstanding indebtedness to SciSparc Ltd. This strategic financial move underscores the company's commitment to advancing its pipeline of novel therapeutics for central nervous system disorders. The offering remains subject to final approval from the TSX Venture Exchange, and all securities issued are subject to a four-month-and-one-day restricted period.
In connection with the first tranche, the company paid C$222,750 in finder's fees and issued 2,812,500 common shares as compensation to a qualified arm's length party. This reflects the company's proactive approach to securing capital while managing costs.
The successful closure of this tranche is a critical step for NeuroThera as it seeks to strengthen its financial position. The funds will enable the company to continue its research and development efforts, explore strategic partnerships, and address existing financial obligations. The potential acceleration of warrant expiry upon a Nasdaq listing could also provide additional flexibility and capital if the company achieves that milestone.
NeuroThera Labs is dedicated to developing treatments for underserved health conditions, particularly in the central nervous system space. This capital infusion is likely to accelerate its progress, though the company faces typical clinical-stage risks, including the need for additional financing and regulatory approvals.
The offering was previously announced on June 30 and July 2, 2026, and this first tranche closure demonstrates continued investor confidence in the company's strategy. As NeuroThera moves forward, stakeholders will be watching for further updates on its development programs and potential Nasdaq listing, which could significantly impact its operational trajectory.
